Bli medlem
Bli medlem

Du är här

2014-05-06

Probi: Probi to launch Probi Digestis® in Turkey

Probi has signed a distribution agreement with Impexia, a
pharmaceutical sales and marketing company well established in the
Turkish market. Impexia plans to launch Probi Digestis® during Q3,
2014.

Turkey is a fast moving economy and has a growing probiotic market
with several new players succesfully launching new probiotic products
lately. The market is expanding and new brands are growing as the
medical community is increasing its appreciation for probiotics.

"Impexia is committed to gain market share in the years to come" says
Peter Nählstedt, CEO of Probi. Mr. Nählstedt adds, "Impexia is a
strong Partner of Probi's with good market access to key geografical
areas in Turkey having high potential for Probi Digestis®. Probi
Digestis®has a large number of positive clinical studies within gut
health such as reduction or elimination of symptoms associated with
Irritable Bowel Syndrome".

Probi Digestis® is based on Lactobacillus plantarum 299v, which
targets bloating, gas formation and pain, common symptoms that are
sometimes mild or temporary but often more severe and causing a low
quality of life for people suffering from such symptoms.

"Probi Digestis® will be launched under the Probi brand in Turkey to
emphasize the high quality probiotic ingredient, invented and further
developed by Probi" says Tayfun Kapcioglu, COO of Impexia, adding:
"Probi Digestis® will be sold via Impexia's field force targeting GPs
and Gastroenterologists and the large number of pharmacies available
in the Turkish market".

"Probi is looking forward to entering the Turkish market and we will
be supporting this key launch through high involvement in the
marketing activities", says Peter Nählstedt. "We are very much
looking forward to a productive cooperation with Impexia in Turkey"

The information is such that Probi AB must disclose in accordance with
the Swedish Securities Market Act and/or the Financial Instruments
Trading Act.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, phone +46 46 286 89 23 or mobile +46 723
86 99 83, e-mail: Peter.Nahlstedt@probi.se

Niklas Bjärum, Vice President Marketing & Sales, Probi, phone +46 46
286 89 67 or mobile +46 705 38 88 64, e-mail: Niklas.Bjarum@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that
develops effective and well-documented probiotics. Through its
research, Probi has created a strong product portfolio in the
gastrointestinal health and immune system areas. The products are
available to consumers in more than 30 countries worldwide. The
customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments.
Probi had sales of MSEK 102 in 2013. The Probi share is listed on
NASDAQ OMX Stockholm, Small-cap. Probi has approximately 3,500
shareholders. Read more on www.probi.se.

ABOUT IMPEXIA
Impexia is a pharmaceutical sales and marketing company with import
from Europe (medical diagnostics) and USA (derma-cosmetics). Impexia
supply more than 5,000 pharmacies throughout Turkey and has strong
media connections providing a unique ability for promotion and
branding.

-----------------------------------------------------------
http://news.cision.com/probi/r/probi-to-launch-probi-digestis--in-turkey...
http://mb.cision.com/Main/1556/9579670/240909.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.